Online citations, reference lists, and bibliographies.
← Back to Search

A Novel Inhibitor Of Gyrase B Is A Potent Drug Candidate For Treatment Of Tuberculosis And Nontuberculosis Mycobacterial Infections

Christopher P Locher, S. Jones, Brian L Hanzelka, E. Perola, C. Shoen, M. Cynamon, A. Ngwane, I. Wiid, P. V. van Helden, Fabrice Betoudji, E. Nuermberger, J. A. Thomson
Published 2014 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
ABSTRACT New drugs to treat drug-resistant tuberculosis are urgently needed. Extensively drug-resistant and probably the totally drug-resistant tuberculosis strains are resistant to fluoroquinolones like moxifloxacin, which target gyrase A, and most people infected with these strains die within a year. In this study, we found that a novel aminobenzimidazole, VXc-486, which targets gyrase B, potently inhibits multiple drug-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis in vitro (MICs of 0.03 to 0.30 μg/ml and 0.08 to 5.48 μg/ml, respectively) and reduces mycobacterial burdens in lungs of infected mice in vivo. VXc-486 is active against drug-resistant isolates, has bactericidal activity, and kills intracellular and dormant M. tuberculosis bacteria in a low-oxygen environment. Furthermore, we found that VXc-486 inhibits the growth of multiple strains of Mycobacterium abscessus, Mycobacterium avium complex, and Mycobacterium kansasii (MICs of 0.1 to 2.0 μg/ml), as well as that of several strains of Nocardia spp. (MICs of 0.1 to 1.0 μg/ml). We made a direct comparison of the parent compound VXc-486 and a phosphate prodrug of VXc-486 and showed that the prodrug of VXc-486 had more potent killing of M. tuberculosis than did VXc-486 in vivo. In combination with other antimycobacterial drugs, the prodrug of VXc-486 sterilized M. tuberculosis infection when combined with rifapentine-pyrazinamide and bedaquiline-pyrazinamide in a relapse infection study in mice. Furthermore, the prodrug of VXc-486 appeared to perform at least as well as the gyrase A inhibitor moxifloxacin. These findings warrant further development of the prodrug of VXc-486 for the treatment of tuberculosis and nontuberculosis mycobacterial infections.
This paper references
10.1128/AAC.00830-09
Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of Tuberculosis
Deepak V. Almeida (2009)
10.1021/jm800318d
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
P. Charifson (2008)
10.1128/AAC.01751-13
Optimization of Pyrrolamides as Mycobacterial GyrB ATPase Inhibitors: Structure-Activity Relationship and In Vivo Efficacy in a Mouse Model of Tuberculosis
Shahul Hameed P (2013)
Bactec MGIT 960 system user’s manual, catalog number 445876
Becton Dickinson (1999)
10.1021/jm500563g
Second-generation antibacterial benzimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability.
A. Grillot (2014)
10.1128/AAC.01903-13
Bactericidal Activity and Mechanism of Action of AZD5847, a Novel Oxazolidinone for Treatment of Tuberculosis
V. Balasubramanian (2013)
10.1021/jm401208b
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
G. Basarab (2013)
aac.asm.org March 2015 Volume 59 Number 3 Antimicrobial Agents and Chemotherapy on Jauary 8, 2018 by gest httpaac.asm .rg/ D ow nladed fom
S Hameed (2014)
10.1093/JAC/DKH124
Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis.
C. Shoen (2004)
aac.asm.org March 2015 Volume 59 Number 3 Antimicrobial Agents and Chemotherapy
S Hameed (2014)
10.1128/AAC.01423-09
Fast Standardized Therapeutic-Efficacy Assay for Drug Discovery against Tuberculosis
J. Rullás (2010)
10.1128/AAC.00055-06
Low-Oxygen-Recovery Assay for High-Throughput Screening of Compounds against Nonreplicating Mycobacterium tuberculosis
Sang Hyun Cho (2007)
10.2174/187152607781001763
Mycobacterium tuberculosis DNA gyrase as a target for drug discovery.
Khisimuzi E Mdluli (2007)
10.1093/jac/dkr449
Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis.
S. Chopra (2012)
10.1021/jm401268f
Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.
M. Kale (2013)
10.1128/AAC.50.4.1228-1237.2006
In Vitro Characterization of the Antibacterial Spectrum of Novel Bacterial Type II Topoisomerase Inhibitors of the Aminobenzimidazole Class
N. Mani (2006)
10.1016/S0272-2712(18)30259-2
Drug Susceptibility Testing
L. Heifets (1996)
10.1128/JCM.36.2.362-366.1998
Rapid, Low-Technology MIC Determination with Clinical Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay
S. Franzblau (1998)
10.1021/cb300510w
Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis.
Pravin S. Shirude (2013)
10.1164/rccm.201103-0397OC
Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
Tianyu Zhang (2011)
10.1128/JCM.44.3.688-692.2006
Multicenter Laboratory Validation of the BACTEC MGIT 960 Technique for Testing Susceptibilities of Mycobacterium tuberculosis to Classical Second-Line Drugs and Newer Antimicrobials
S. Rüsch-Gerdes (2006)
10.3201/EID1903.120246
Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa.
M. Klopper (2013)
10.3201//EID1903.120246
Emergence and Spread of Extensively and Totally Drug-Resistant Tuberculosis, South Africa
M. Klopper (2013)
aac.asm.org March 2015 Volume 59 Number 3 Antimicrobial Agents and Chemotherapy on July 31, 2017 by gest httpaac.asm .rg/ D ow nladed fom
S Hameed (2014)
10.1016/j.bmcl.2013.12.080
Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy.
Ramesh R. Kale (2014)
10.1371/journal.pone.0084409
Tricyclic GyrB/ParE (TriBE) Inhibitors: A New Class of Broad-Spectrum Dual-Targeting Antibacterial Agents
L. W. Tari (2013)
10.1002/cmdc.201402035
Gyrase ATPase Domain as an Antitubercular Drug Discovery Platform: Structure‐Based Design and Lead Optimization of Nitrothiazolyl Carboxamide Analogues
V. U. Jeankumar (2014)
10.1128/IAI.72.2.1065-1071.2004
Paucibacillary Tuberculosis in Mice after Prior Aerosol Immunization with Mycobacterium bovis BCG
E. Nuermberger (2004)
10.1111/j.1749-6632.2011.06330.x
The oxazolidinones: past, present, and future
K. Shaw (2011)
10.1016/j.bmcl.2012.11.073
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.
Micheal Trzoss (2013)
Global tuberculosis report (2014)
L. A. Gabbasova (2014)
10.1124/PR.58.3.10
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
T. Chou (2006)
10.1128/AAC.00596-06
Dual Targeting of GyrB and ParE by a Novel Aminobenzimidazole Class of Antibacterial Compounds
T. Grossman (2006)
10.1128/AAC.41.1.101
In vitro activity of BAY 12-8039, a new fluoroquinolone.
J. Woodcock (1997)
Clinical mycobacteriology. Drug susceptibility testing.
L. Heifets (1996)
10.1128/AAC.02718-14
In Vitro Activity of AZD5847 against Geographically Diverse Clinical Isolates of Mycobacterium tuberculosis
J. Werngren (2014)
10.1164/rccm.200905-0795OC
Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
Tianyu Zhang (2009)
10.1371/journal.pone.0094462
Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis
R. Wallis (2014)



This paper is referenced by
10.3390/app10124248
Structure-Based Drug Design for Tuberculosis: Challenges Still Ahead
E. Bruch (2020)
10.1016/j.drudis.2016.09.006
New prodrugs against tuberculosis.
G. Mori (2017)
10.1016/j.bmcl.2016.09.043
Identification and optimization of a new series of anti-tubercular quinazolinones.
C. Couturier (2016)
10.1016/j.bmcl.2017.07.067
2-N-Arylthiazole inhibitors of Mycobacterium tuberculosis.
M. P. Clark (2017)
10.1128/AAC.01503-18
In Vitro Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria
B. Brown-Elliott (2018)
10.4155/fmc-2016-0042
Targeting bacterial topoisomerases: how to counter mechanisms of resistance.
Yuk-Ching Tse-Dinh (2016)
10.1038/s41429-020-0291-8
Antibiotics in the clinical pipeline in October 2019
M. Butler (2020)
10.3389/fmolb.2017.00075
Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis
M. Reiche (2017)
10.2174/1568026619666190304130218
Targeting DNA Gyrase to Combat Mycobacterium tuberculosis: An Update.
Swetarka Das (2019)
10.3389/fchem.2020.586294
Handling the Hurdles on the Way to Anti-tuberculosis Drug Development
P. F. Dalberto (2020)
10.1080/1120009X.2017.1338845
News on therapeutic management of MDR-tuberculosis: a literature review
L. Barthod (2018)
10.1002/iub.2002
The evaluation of the anti‐cancer drug elesclomol that forms a redox‐active copper chelate as a potential anti‐tubercular drug
A. Ngwane (2019)
10.1016/j.trsl.2020.03.007
New tuberculosis drug targets, their inhibitors and potential therapeutic impact.
Gauri S Shetye (2020)
10.3390/ijms20122868
Opportunities for Overcoming Mycobacterium tuberculosis Drug Resistance: Emerging Mycobacterial Targets and Host-Directed Therapy
Eveline Torfs (2019)
Strategies to improve treatment of nontuberculous mycobacterial disease
Belén Ramos (2017)
10.1080/14656566.2020.1793958
Pharmacotherapeutic management of bronchial infections in adults: non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease
M. D. Di Pasquale (2020)
10.3390/ijms21186793
Alternative and Experimental Therapies of Mycobacterium abscessus Infections
Michal Meir (2020)
10.1128/AAC.02821-15
Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease
Beatriz E. Ferro (2016)
10.3389/fmicb.2017.01539
Screening of TB Actives for Activity against Nontuberculous Mycobacteria Delivers High Hit Rates
Jian Liang Low (2017)
10.1183/2312508X.10005716
Perspectives on antibiotic treatment of NTM pulmonary disease
Nicolas Schönfeld (2017)
10.1128/AAC.00459-15
Susceptibility of Mycobacterium abscessus to Antimycobacterial Drugs in Preclinical Models
A. Obregón-Henao (2015)
Médicaments et molécules innovantes en développement pour la prise en charge de la tuberculose
Léo Faïon (2019)
10.3390/antibiotics9010018
Looking beyond Typical Treatments for Atypical Mycobacteria
Clara M Bento (2020)
10.1080/07391102.2016.1277784
Dynamics of fluoroquinolones induced resistance in DNA gyrase of Mycobacterium tuberculosis
B. Pandey (2018)
10.1080/13543776.2019.1575362
ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents
Martina Durcik (2019)
10.1080/14787210.2016.1238304
Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment
F. Mougari (2016)
10.4155/fmc-2017-0257
Recent progress in the discovery and development of DNA gyrase B inhibitors.
M. Barančoková (2018)
10.1038/s41579-020-0331-1
Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus
Matt D. Johansen (2020)
Semantic Scholar Logo Some data provided by SemanticScholar